Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus cetuximab in pretreated KRAS-mutant metastatic colorectal cancer
2009-012665-61Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Celgene Corporation. Primary endpoint: Phase 2a primary endpoint. Started Aug 2009; status: completed.
02
Drugs
lenalidomidecetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-012665-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012665-61.